PMID- 32879878
OWN - NLM
STAT- MEDLINE
DCOM- 20210527
LR  - 20210527
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2020
DP  - 2020
TI  - Relation of Fibrinogen-to-Albumin Ratio to Severity of Coronary Artery Disease 
      and Long-Term Prognosis in Patients with Non-ST Elevation Acute Coronary 
      Syndrome.
PG  - 1860268
LID - 10.1155/2020/1860268 [doi]
LID - 1860268
AB  - Previous studies showed that fibrinogen-to-albumin ratio (FAR) regarded as a 
      novel inflammatory and thrombotic biomarker was the risk factor for coronary 
      artery disease (CAD). In this study, we sought to evaluate the relationship 
      between FAR and severity of CAD, long-term prognosis in non-ST elevation acute 
      coronary syndrome (NSTE-ACS) patients firstly implanted with drug-eluting stent 
      (DES). A total of 1138 consecutive NSTE-ACS patients firstly implanted with DES 
      from January 2017 to December 2018 were recruited in this study. Patients were 
      divided into tertiles according to FAR levels (Group 1: </=8.715%; Group 2: 
      8.715%~10.481%; and Group 3: >10.481%). The severity of CAD was evaluated using 
      the Gensini Score (GS). The endpoints were major adverse cardiovascular events 
      (MACE), including all-cause mortality, myocardial reinfarction, and target vessel 
      revascularization (TVR). Positive correlation was detected by Spearman's rank 
      correlation coefficient analysis between FAR and GS (r = 0.170, P < 0.001). On 
      multivariate logistic analysis, FAR was an independent predictor of severe CAD 
      (OR: 1.060; 95% CI: 1.005~1.118; P < 0.05). Multivariate Cox regression analysis 
      indicated that FAR was an independent prognostic factor for MACE at 30 days, 6 
      months, and 1 year after DES implantation (HR: 1.095; 95% CI: 1.011~1.186; P = 
      0.025. HR: 1.076; 95% CI: 1.009~1.147; P = 0.026. HR: 1.080; 95% CI: 1.022~1.141; 
      P = 0.006). Furthermore, adding FAR to the model of established risk factors, the 
      C-statistic increased from 0.706 to 0.720, 0.650 to 0.668, and 0.611 to 0.632, 
      respectively. And the models had incremental prognostic value for MACE, 
      especially for 1-year MACE (NRI: 13.6% improvement, P = 0.044; IDI: 0.6% 
      improvement, P = 0.042). In conclusion, FAR was associated independently with the 
      severity of CAD and prognosis, helping to improve risk stratification in NSTE-ACS 
      patients firstly implanted with DES.
CI  - Copyright (c) 2020 Mingkang Li et al.
FAU - Li, Mingkang
AU  - Li M
AD  - School of Medicine, Southeast University, Nanjing, Jiangsu, China.
FAU - Tang, Chengchun
AU  - Tang C
AUID- ORCID: 0000-0003-3767-3551
AD  - Department of Cardiology, Zhongda Hospital, Southeast University, Nanjing, 
      Jiangsu, China.
FAU - Luo, Erfei
AU  - Luo E
AD  - School of Medicine, Southeast University, Nanjing, Jiangsu, China.
FAU - Qin, Yuhan
AU  - Qin Y
AD  - School of Medicine, Southeast University, Nanjing, Jiangsu, China.
FAU - Wang, Dong
AU  - Wang D
AD  - Department of Cardiology, Zhongda Hospital, Southeast University, Nanjing, 
      Jiangsu, China.
FAU - Yan, Gaoliang
AU  - Yan G
AUID- ORCID: 0000-0003-2563-167X
AD  - Department of Cardiology, Zhongda Hospital, Southeast University, Nanjing, 
      Jiangsu, China.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20200817
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Serum Albumin)
RN  - 0 (Troponin I)
RN  - 9001-32-5 (Fibrinogen)
RN  - EC 2.7.3.2 (Creatine Kinase, MB Form)
SB  - IM
MH  - Acute Coronary Syndrome/blood/*etiology/therapy
MH  - Aged
MH  - Cardiovascular Diseases/epidemiology/etiology
MH  - Coronary Artery Disease/blood/*etiology/therapy
MH  - Creatine Kinase, MB Form/blood
MH  - Drug-Eluting Stents
MH  - Electrocardiography
MH  - Female
MH  - Fibrinogen/*analysis
MH  - Humans
MH  - Incidence
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Prospective Studies
MH  - Risk Factors
MH  - Serum Albumin/*analysis
MH  - Troponin I/blood
PMC - PMC7448116
COIS- The authors certify that they have no affiliations with or involvement in any 
      organization or entity with any financial interest or nonfinancial interest in 
      the subject matter or materials discussed in this manuscript.
EDAT- 2020/09/04 06:00
MHDA- 2021/05/28 06:00
PMCR- 2020/08/17
CRDT- 2020/09/04 06:00
PHST- 2020/05/21 00:00 [received]
PHST- 2020/07/20 00:00 [revised]
PHST- 2020/08/05 00:00 [accepted]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2021/05/28 06:00 [medline]
PHST- 2020/08/17 00:00 [pmc-release]
AID - 10.1155/2020/1860268 [doi]
PST - epublish
SO  - Biomed Res Int. 2020 Aug 17;2020:1860268. doi: 10.1155/2020/1860268. eCollection 
      2020.